Navigation Links
Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy
Date:3/25/2008

Pipeline of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management. The company has one FDA-approved product, Zingo(TM), for the reduction of pain associated with peripheral venous access procedures in children ages three to 18. In clinical trials, the most common adverse reactions to Zingo were redness (erythema), red dots (petechiae) and swelling (edema). The second product in Anesiva's pipeline, Adlea(TM), reduces pain after only a single administration for weeks to months based on mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain. Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.

Forward Looking Statements

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this press release include matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results expressed or implied by this press release. Such risk factors include, among others: the timing and results of our clinical trials, and our regulatory approval strategy for Adlea. Actual results may differ materially from those cont
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
2. Anesiva Defines Regulatory Pathway for Adlea with FDA
3. Anesiva Initiates Phase 2 Trial with Adlea(TM) for Pain Relief Following Total Hip Replacement Surgery
4. Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery
5. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
6. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
7. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
8. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
9. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
10. Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
11. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2008)...EAPOLIS, July 22 /- Nonin Medical, a ...tions for more than 20 years, has entered,the clin...y to measure,regional oxygen saturation. Today,s m...continuous monitoring of the regional blood oxygen...esting data and outcomes from an ongoing clinical ...
(Date:7/22/2008)...DA Meeting to Discuss Development Plan Completed S...-FirstCall/ -- Amarin Corporation,plc (NASDAQ: AM... with,officials at the U.S. Food and Drug Administ...elop AMR101 for the treatment of,hypertriglyceride...roceeding to Phase 3 with AMR101 in hypertriglycer...
(Date:7/22/2008)...-of-the-Art PET Study Confirms Tyrima Exhibits Exc...erties - - Results Support Initiation of Pha...N.C., July 22 /- CeNeRx BioPharma,In...cializing innovative,treatments for diseases of th... advance its lead candidate Tyrima(TM) into Phase ...
(Date:7/22/2008)...eoffrey Allan Will Stress the Importance to Patien...cs Approval Pathway, RICHMOND, Va., July 22 /PRNe... a developer of follow-on biologics and biopharmac...D., CEO of Insmed, will present at a,Congressional...e,significant need for establishing an approval pa...
Breaking Medicine Technology:Nonin Medical Inc. Announces Entry Into the Cerebral Oximeter Market 2Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 2Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 2CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 4Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 2Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 3Serum sodium predicts mortality 10 times higher in PAH patients 21781 1Serum sodium predicts mortality 10 times higher in PAH patients 21781 2New Long Term HUMIRA 28R 29 28adalimumab 29 Data Show Up to Seven Year Efficacy with Combination Treatment for Rheumatoid Arthritis 21779 1New Long Term HUMIRA 28R 29 28adalimumab 29 Data Show Up to Seven Year Efficacy with Combination Treatment for Rheumatoid Arthritis 21779 2New Long Term HUMIRA 28R 29 28adalimumab 29 Data Show Up to Seven Year Efficacy with Combination Treatment for Rheumatoid Arthritis 21779 3New Long Term HUMIRA 28R 29 28adalimumab 29 Data Show Up to Seven Year Efficacy with Combination Treatment for Rheumatoid Arthritis 21779 4New Long Term HUMIRA 28R 29 28adalimumab 29 Data Show Up to Seven Year Efficacy with Combination Treatment for Rheumatoid Arthritis 21779 5New Long Term HUMIRA 28R 29 28adalimumab 29 Data Show Up to Seven Year Efficacy with Combination Treatment for Rheumatoid Arthritis 21779 6New Long Term HUMIRA 28R 29 28adalimumab 29 Data Show Up to Seven Year Efficacy with Combination Treatment for Rheumatoid Arthritis 21779 71 in 8 Lower Manhattan residents had signs of PTSD 2 to 3 years after 9 11 21776 11 in 8 Lower Manhattan residents had signs of PTSD 2 to 3 years after 9 11 21776 2Membrane complexes take flight 5975 1Membrane complexes take flight 5975 2
... Risk of Late Thrombosis is Minimized with Genous ... -- The efficacy of,OrbusNeich,s Genous(TM) Bio-en...g-eluting stents, while the risk of late thrombosi... an interim,analysis of post-marketing data presen...roPCR 2007 in Barcelona, Spain. , Collected from m...
... PRINCETON, N.J.--(BUSINESS WIRE)--May 23, 2007 - ...the publication of a,review validating the utility...unction of the WW domain-containing oxidoreductase...nown involvement,in breast, prostate, lung, pancre...viewed article was published in the online,edition...
Other Medicine Technology:Efficacy of OrbusNeich's Genous Bio-Engineered R Stent Compares,Favorably to Drug-Eluting Stents 2Efficacy of OrbusNeich's Genous Bio-Engineered R Stent Compares,Favorably to Drug-Eluting Stents 3Cytogen Reports Publication Validating the Utility of its,Proprietary ProChart Database 2Cytogen Reports Publication Validating the Utility of its,Proprietary ProChart Database 3Cytogen Reports Publication Validating the Utility of its,Proprietary ProChart Database 4
(Date:7/25/2008)... firm represents Pickerington man who contracted E... Kroger store , Columbus,...onaheyohioinjurylawyers.com [The Donahey Law Firm... central Ohio, has filed a product liability lawsu...ainst The Kroger Co., in connection with an E. col...
(Date:7/24/2008)...ital facility on Sand Canyon Avenue , ...08 -- Hoag Memorial Hospital Presbyterian has reac...l Estate Investment Trust headquartered in Long Be... Sand Canyon Avenue near the 405 freeway in Irvine...d by Tenet Healthcare Corporation (NYSE: THC) as I...
(Date:7/24/2008)...stCall/ -- ev3 Inc. (Nasdaq:,EVVV) today announced...and,year-to-date financial results. ev3 will now r...ancial results on Monday, July 28, 2008, after reg... a conference call and webcast at 7:30 a.m.,Centra...9, 2008. ev3,management will review its second qua...
(Date:7/24/2008)...ine Annual Report Experience it at http:/...f., July 24 /PRNewswire/ -- Are you an e-patient?,...users go online for,health information. Thanks to ...re personal health experiences, shop for health ca...Go to http://SutterHealth.org/annualreport ,and y...
Breaking Medicine News(10 mins):Health News:Donahey Law Firm Files E. Coli Product Liability Lawsuit Against Kroger Company in Franklin County Court 2Health News:Hoag Hospital Announces Agreement to Open Irvine Campus 2Health News:ev3 Inc. Announces Revised Date for 2008 Second Quarter Financial Results and Conference Call 2Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 2Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 3Health News:Internet Video Revolution - Sutter Health Harnesses Power of Web 2.0 to Inform Customers 4
...allergic reaction has been widely reported by wome...in associated with burning in their groin and geni... confirmed by doctors as a true case of allergy th...Thankfully doctors have given the hope to such wom...
...imens to treat HIV infection that are based on a n...TI) are at least as effective as treatment with a ...fewer pills each day, according to a new study fun...are Research and Quality. The study, published in...
... Delhi: The Health and Family Welfare pavilion at ...rated by Dr. Anbumani Ramadoss//, Minister for Hea...he occasion, the Minister said the ambience to the... rural necessities, as their focus in the National...
...is- Scientists from the Mecca of Fashion, Paris, h... the presence of a natural chemical called opiorph... than the well known morphine. In their experiment...in relief with a reduced dosage of this chemical i...
Other Medicine News:Health News:See, men cause allergies in women after sex 2Health News:A More Convenient HIV Treatment Is as Effective as More Complex Regimens 2Health News:A More Convenient HIV Treatment Is as Effective as More Complex Regimens 3
...Ovulation Predicting Test is a qualitative immunoa...e (hLH) in human urine to predict the occurrence o...on of human luteinizing hormone (hLH). Usually, ar...rief, significant rapid increase called the "LH su...
The Shandon Cryotome SME Cryostat model is a sophisticated, top of the line cryostat that combines automated electronic advance and hands-free sectioning with fully independent specimen temperature c
The Shandon Linistat Linear Stainer is a compact answer to H&E frozen section protocols, with a footprint that fits on top of most cryostas to streamline workflow during frozen sectioning.
The Shandon Varistain Gemini is designed for high throughput, precision, safety, durability and ultimate flexibility in histology and cytology staining applications. It features load-on-demand multip
Medicine Products: